Elevated PD-L1 expression on plasma sEVs during anti-PD-1 immunotherapy was linked to successful therapy response in melanoma patients [126], and high PD-L1 mRNA expression on circulating sEVs from melanoma and NSCLC patients before anti-PD-1 treatment was correlated with partial or complete remission after therapy [127]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.